Phospho-GATA4 (S105) Antibody

What is the biological significance of GATA4 phosphorylation at serine 105?

Phosphorylation of GATA4 at serine 105 (S105) is a critical post-translational modification that significantly enhances GATA4's transcriptional potency, DNA binding activity, and ability to regulate gene expression in cardiac tissue. This specific phosphorylation is induced in response to stress stimulation or injury and plays a crucial role in cardiac hypertrophy and remodeling processes. Studies utilizing knock-in mice with GATA4-S105A mutation (preventing phosphorylation at this site) demonstrate that S105 phosphorylation is necessary for productive cardiac hypertrophy in response to pressure overload stimulation and neurohormonal stress . When this phosphorylation is blocked, hearts show compromised stress responses, blunted hypertrophic growth, increased susceptibility to heart failure, and cardiac dilation under pressure overload conditions .

Which signaling pathways regulate GATA4 S105 phosphorylation?

GATA4 is directly phosphorylated at S105 primarily by two mitogen-activated protein kinases (MAPKs): extracellular signal-regulated kinases 1/2 (ERK1/2) and p38 MAPK. These kinases function downstream of neuroendocrine stress signaling pathways known to drive cardiac hypertrophic responses. In experimental models, ERK1/2 and p38 MAPK activity are necessary for increased GATA4 DNA binding that occurs following acute cardiac wall stretching . Several studies confirm this regulatory pathway:

• Hepatocyte growth factor treatment of cultured cardiomyocytes induces S105 phosphorylation, which is abolished by MEK1-ERK1/2 signaling inhibitors

• Endothelin-1 stimulation of cardiac fibroblasts activates GATA4 via S105 phosphorylation, which can be blocked with MEK1-ERK1/2 inhibitors

• Experiments with activated MEK1 transgenic mice demonstrate that ERK1/2 signaling is a required mediator of GATA4 induction during hypertrophy specifically through the S105 site

How does phosphorylation at S105 alter GATA4 function at the molecular level?

Phosphorylation at S105 enhances GATA4 function through several molecular mechanisms:

• Enhanced DNA binding: Phosphorylation significantly increases GATA4's affinity for its DNA recognition sequences. This has been demonstrated in protein extracts from hearts subjected to acute wall stretching, where increased GATA4 DNA binding was observed .

• Transcriptional potency: S105 phosphorylation augments GATA4's ability to activate transcription. Gene array profiling comparing wild-type and GATA4-S105A mutant hearts revealed significant alterations in gene expression patterns .

• Target gene regulation: Microarray analysis identified 83 up-regulated and 159 down-regulated genes in S105A mutant hearts compared to wild-type, indicating that this phosphorylation is required for normal regulation of a substantial gene program .

• Cardiac gene program modulation: S105 phosphorylation particularly affects genes related to the extracellular matrix (ECM) and the fetal gene program associated with hypertrophy (including Nppa, Nppb, Myh7, Myh6) .

What methods can detect GATA4 S105 phosphorylation in cardiac tissue?

Detection of GATA4 S105 phosphorylation in cardiac tissue requires specific techniques:

• Phospho-specific antibodies: The most direct method utilizes antibodies that specifically recognize GATA4 only when phosphorylated at S105. This approach has been validated in multiple studies, including detection of increased S105 phosphorylation in response to acute pressure overload stimulation in mouse hearts .

• Western blotting protocol:

  • Sample preparation: Cardiac tissue homogenization in buffer containing phosphatase inhibitors is essential

  • Protein separation: 10-12% SDS-PAGE gels

  • Transfer: Nitrocellulose or PVDF membranes

  • Blocking: 5% BSA in TBST (typically more effective than milk for phospho-epitopes)

  • Primary antibody incubation: Anti-phospho-GATA4 (S105) antibody (1:1000 dilution, overnight at 4°C)

  • Detection: HRP-conjugated secondary antibodies with ECL detection

• Immunohistochemistry/Immunofluorescence: Fixed cardiac tissue sections can be probed with phospho-specific antibodies to visualize spatial distribution of S105-phosphorylated GATA4 in the myocardium.

• Controls: Always include S105A mutant samples as negative controls to validate antibody specificity, as mutation of this site precludes antibody binding .

How can I validate Phospho-GATA4 (S105) Antibody specificity?

Antibody validation is critical for reliable results. Multiple approaches should be employed:

• Genetic controls: Test the antibody on samples from GATA4-S105A mutant mice or cells expressing S105A-mutated GATA4, which should show no signal despite normal GATA4 protein levels .

• Phosphatase treatment: Treat half of your protein sample with lambda phosphatase before immunoblotting; phosphatase-treated samples should show dramatically reduced signal.

• Stimulation experiments: Compare basal versus stimulated samples (e.g., pressure overload, agonist treatment) to confirm increased signal after treatments known to induce S105 phosphorylation.

• Peptide competition: Pre-incubate antibody with phosphorylated and non-phosphorylated peptides corresponding to the S105 region to demonstrate specificity for the phosphorylated epitope.

• Double validation: Use multiple antibodies from different sources/clones to confirm consistent results.

How do the phenotypes of GATA4-S105A mutant models compare to GATA4 knockout models?

The phenotypic comparison between phosphorylation-deficient GATA4-S105A models and complete GATA4 knockout models reveals distinct roles for S105 phosphorylation versus total GATA4 function:

This comparison demonstrates that while complete GATA4 absence is incompatible with cardiac development, specific loss of S105 phosphorylation primarily affects stress-responsive pathways while preserving baseline cardiac function. This suggests that S105 phosphorylation represents a stress-activated regulatory mechanism rather than a constitutively required function .

What gene expression changes occur in GATA4-S105A mutant hearts?

Affymetrix-based microarray analysis of GATA4-S105A mutant hearts revealed substantial gene expression alterations compared to wild-type controls. These changes affect several key pathways:

• ECM and remodeling genes: Many genes related to extracellular matrix composition and remodeling were significantly altered .

• Fetal gene program: Genes comprising the classical cardiac fetal gene program showed altered expression, particularly notable since many have direct GATA4 binding sites in their promoters .

Specific down-regulated genes in S105A mutant hearts include:

• Contractile proteins: Myh7, Myh6

• Natriuretic peptides: Nppb

• Growth factors: Fgf16

• Matrix and remodeling genes: Spp1, Cthrc1, Col1a2, Ctgf, Thbs4, Col3a1, Ltpb2, Tgfbi, Timp1, Fstl4

Conversely, Ephbi and Fgf2 were up-regulated in S105A mutant hearts . These expression changes likely underlie the impaired ability of these hearts to productively hypertrophy under stress conditions.

How does GATA4 phosphorylation status affect cardiac fibroblast function?

GATA4 phosphorylation at S105 appears to play a critical role in cardiac fibroblast function and fibrotic gene expression:

• Differential gene regulation: In studies with isolated neonatal rat ventricular fibroblasts (NRVFs), wild-type GATA4 overexpression induced small increases in fibrotic markers like FN1, Col1a1, and MMP2, while decreasing MMP9 expression. In contrast, GATA4-S105A mutant overexpression significantly reduced the expression of multiple fibrotic genes including FN1, Col1a1, Col3a1, MMP2, TIMP1, FGF2, and PEX1 .

• In vivo fibrotic response: In angiotensin II-induced hypertension models, wild-type GATA4 overexpression repressed fibrotic gene expression and prevented apoptosis, while GATA4-S105A mutant overexpression had minimal effects on myocardial remodeling genes .

• Fibroblast-specific effects: Studies with isolated cardiac fibroblasts confirm that GATA4's effects on fibrotic gene expression are directly mediated in fibroblasts and depend on S105 phosphorylation .

These findings demonstrate that GATA4 S105 phosphorylation status differentially regulates fibrotic gene expression programs, with important implications for cardiac remodeling and fibrosis development.

What are the key experimental controls when studying GATA4 S105 phosphorylation?

When designing experiments to study GATA4 S105 phosphorylation, several critical controls should be incorporated:

• Phosphorylation site mutants: Include GATA4-S105A mutants (serine to alanine mutation) as negative controls that cannot be phosphorylated at this site .

• Kinase pathway modulators: Include conditions with specific inhibitors of ERK1/2 and p38 MAPK pathways to confirm the kinase dependency of observed phosphorylation events .

• Time course analysis: Monitor phosphorylation changes at multiple time points following stimulus application, as phosphorylation can be transient.

• Stimulus intensity gradation: Use varying concentrations/intensities of hypertrophic stimuli to establish dose-response relationships.

• Cell type controls: Compare responses across cardiomyocytes and cardiac fibroblasts, as GATA4 functions differently in these cell types .

• Phosphatase controls: Include samples treated with phosphatases to demonstrate that observed effects are phosphorylation-dependent.

• Gainand loss-of-function: Combine overexpression of wild-type GATA4 with knockdown/knockout approaches to comprehensively assess function.

How can I distinguish between direct and indirect effects of GATA4 S105 phosphorylation?

Distinguishing direct from indirect effects requires specialized experimental approaches:

• Chromatin immunoprecipitation (ChIP): Perform ChIP with phospho-specific GATA4 antibodies to identify genomic loci directly bound by S105-phosphorylated GATA4.

• Cell-type specific manipulations: When using in vivo models like intramyocardial adenoviral delivery, remember that effects observed may reflect changes in both infected and non-infected cells, as well as direct and indirect effects across multiple cardiac cell types .

• Paracrine signaling assessment: Since GATA4 is predominantly overexpressed in cardiomyocytes in the adult heart, changes in cardiac gene expression may partly reflect paracrine effects on neighboring cells .

• Transactivation assays: Use reporter constructs with known GATA4 binding sites to assess direct transcriptional effects of wild-type versus S105A GATA4.

• Inducible systems: Employ temporally controlled expression systems to distinguish between immediate (likely direct) and delayed (potentially indirect) effects of GATA4 S105 phosphorylation.

What are common challenges in detecting GATA4 S105 phosphorylation?

Researchers often encounter several challenges when studying GATA4 S105 phosphorylation:

• Signal specificity: Phospho-specific antibodies may show cross-reactivity with other phosphorylated epitopes, necessitating thorough validation with S105A mutant controls .

• Phosphorylation dynamics: GATA4 S105 phosphorylation can be rapid and transient, requiring careful timing of sample collection.

• Phosphatase activity: Endogenous phosphatases in tissue samples can rapidly dephosphorylate GATA4 during extraction, making phosphatase inhibitors critical in all buffers.

• Tissue heterogeneity: When analyzing whole cardiac tissue, varying cell type compositions can obscure cell-specific phosphorylation patterns.

• Antibody sensitivity: Low-abundance phosphorylated forms may require enrichment techniques like immunoprecipitation before detection.

• Stimulus specificity: Different hypertrophic stimuli (pressure overload, neurohormonal factors) may induce different patterns or kinetics of S105 phosphorylation .

How do experimental models of GATA4 S105 phosphorylation compare to human cardiac disease?

Translating findings from experimental models to human cardiac disease requires careful consideration:

• Species differences: While GATA4 S105 is conserved across species, regulatory kinase networks may differ between rodents and humans.

• Disease complexity: Experimental models like pressure overload or angiotensin II infusion represent simplified versions of complex human cardiac diseases with multiple pathological processes.

• Temporal aspects: Acute experimental manipulations may not fully recapitulate chronic disease processes in humans.

• Genetic background effects: Studies in inbred mouse lines may miss genetic modifiers important in diverse human populations.

• Therapeutic implications: While GATA4 S105 phosphorylation appears protective in experimental models, the translational potential requires further investigation in human samples.

• Model validation: Local intramyocardial delivery of adenoviral constructs represents a cardiac-specific approach for gene delivery that mimics pharmacotherapy approaches, but limits expression to a portion of cells surrounding the injection area .